共 36 条
- [35] Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
- [36] STUDY ESOGIA-GFPC 08-02-PHASE III, RANDOMIZED, MULTICENTER TRIAL INVOLVING SUBJECTS OVER 70 YEARS OF AGE WITH NON SMALL-CELL LUNG CANCER OF STAGE IV AND COMPARING A "CLASSICAL" STRATEGY OF TREATMENT ALLOCATION (DUAL-AGENT THERAPY BASED ON CARBOPLATIN OR MONOTHERAPY WITH DOCETAXEL ALONE), BASED ON PERFORMANCE STATUS AND AGE, WITH AN "OPTIMIZED" STRATEGY ALLOCATING THE SAME TREATMENTS ACCORDING TO A SIMPLIFIED GERIATRIC SCREENING SCALE, PLUS A MORE THOROUGH GERIATRIC EVALUATION IF NECESSARY. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S556 - S556